That ended in 2013, when the Supreme Court ruled that pay-for-delay deals could violate antitrust law even under those circumstances. That’s because the deals typically were struck while the patent challenges were still in court and therefore could go either way. The generics makers, therefore, were kept out of the market by patent-holders whose patents actually might not be valid.

Source: Los Angeles Times February 20, 2019 22:41 UTC